Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Feb 14, 2022

SELL
$10.52 - $16.96 $2.89 Million - $4.66 Million
-275,000 Closed
0 $0
Q3 2021

Nov 15, 2021

SELL
$9.82 - $15.23 $1.23 Million - $1.9 Million
-125,000 Reduced 31.25%
275,000 $3.47 Million
Q1 2021

May 17, 2021

BUY
$25.6 - $32.0 $10.2 Million - $12.8 Million
400,000 New
400,000 $11.3 Million

Others Institutions Holding IKNA

About Ikena Oncology, Inc.


  • Ticker IKNA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 36,257,500
  • Market Cap $61.6M
  • Description
  • Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. I...
More about IKNA
Track This Portfolio

Track Octagon Capital Advisors LP Portfolio

Follow Octagon Capital Advisors LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Octagon Capital Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on Octagon Capital Advisors LP with notifications on news.